Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1093/jac/dkaa442 http://scihub22266oqcxt.onion/10.1093/jac/dkaa442 33099620!7665528!33099620     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       J+Antimicrob+Chemother 2021 ; 76 (2): 283-285 Nephropedia Template TP {{tp|p=33099620|t=2021. Treating COVID-19: are we missing out the window of opportunity?|pdf=|usr=}}{{33099620}} gab.com Text Treating COVID-19: are we missing out the window of opportunity JO: J Antimicrob Chemother http://www.kidney.de/pget.php?&tw=1&pmid=33099620 #FOAvip Severe COVID-19 is a biphasic illness, with an initial viral replication phase, followed by a cascade of inflammatory events. Progression to severe disease is predominantly a function of the inflammatory cascade, rather than viral replication per se. This understanding can be effectively translated to changing our approach in managing the disease. The natural course of disease offers us separate windows of specific time intervals to administer either antiviral or immunomodulatory therapy. Instituting the right attack at the right time would maximize the benefit of treatment. This concept must also be factored into studies that assess the efficacy of antivirals and immunomodulatory agents against COVID-19. Twit Text FOAVip Treating COVID-19: are we missing out the window of opportunity ????J Antimicrob Chemother http://www.kidney.de/pget.php?&tw=1&pmid=33099620 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33099620 #FOAvip English Wikipedia <ref>{{Cite pmid|33099620}}</ref> Treating COVID-19: are we missing out the window of opportunity? #MMPMID33099620 Sundararaj Stanleyraj J; Sethuraman N; Gupta R; Thiruvoth S; Gupta M; Ryo A J Antimicrob Chemother 2021[Jan]; 76 (2): 283-285 PMID33099620show ga Severe COVID-19 is a biphasic illness, with an initial viral replication phase, followed by a cascade of inflammatory events. Progression to severe disease is predominantly a function of the inflammatory cascade, rather than viral replication per se. This understanding can be effectively translated to changing our approach in managing the disease. The natural course of disease offers us separate windows of specific time intervals to administer either antiviral or immunomodulatory therapy. Instituting the right attack at the right time would maximize the benefit of treatment. This concept must also be factored into studies that assess the efficacy of antivirals and immunomodulatory agents against COVID-19. |*COVID-19 Drug Treatment[MESH] |*Time-to-Treatment[MESH] |Antiviral Agents/*administration & dosage/therapeutic use[MESH] |COVID-19/immunology/virology[MESH] |Cytokines/blood[MESH] |Disease Progression[MESH] |Humans[MESH] |Immunomodulation/*drug effects/immunology[MESH] |Immunosuppressive Agents/*administration & dosage/therapeutic use[MESH] |SARS-CoV-2/drug effects[MESH]Treating COVID-19: are we missing out the window of opportunity?(epmc).pdf DeepDyve Pubget Overpricing